GT Biopharma (GTBP) Capital Expenditures (2017 - 2018)
GT Biopharma (GTBP) posted quarterly Capital Expenditures of $32000.0 for Q4 2018, up 700.0% year-over-year from $4000.0 in Q4 2017, and up 1500.0% quarter-over-quarter from $2000.0 in Q3 2018.
GT Biopharma (GTBP) Capital Expenditures (2017 - 2018) Analysis & Trends
GT Biopharma (GTBP) has reported Capital Expenditures for 2 consecutive years, with $32000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Capital Expenditures rose 700.0% year-over-year to $32000.0; the TTM figure through Sep 2019 stood at $32000.0 (up 300.0% YoY), while the FY2018 annual figure was $36000.0, up 800.0% from the prior year.
- Capital Expenditures advanced to $32000.0 in Q4 2018 per GTBP's latest filing, from $2000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $32000.0 in Q4 2018 and bottomed at $2000.0 in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | GT Biopharma | 8.64 Mn | 8.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 32,000.00 |
| Dec 31, 2018 | 32,000.00 |
| Sep 30, 2018 | 2,000.00 |
| Sep 30, 2018 | 2,000.00 |
| Mar 31, 2018 | 2,000.00 |
| Mar 31, 2018 | 2,000.00 |
| Dec 31, 2017 | 4,000.00 |
| Dec 31, 2017 | 4,000.00 |